Patents Assigned to Transgene
-
Patent number: 11969462Abstract: The present invention generally relates to a personalized cancer vaccine comprising a recombinant poxvirus encoding one or more neopeptide(s) or a composition comprising such a recombinant poxvirus and a pharmaceutically acceptable vehicle as well as the use of the personalized cancer vaccine for treating a cancerous subject in need thereof. A specific embodiment is directed to a method of providing such a vaccine or composition comprising an identification step comprising a) extracting the DNA from a tumor sample and a non-tumor sample, b) selecting target regions, c) sequencing the target regions from the extracted DNAs and d) identifying one or more tumor-specific mutation(s) by comparing the DNA sequences obtained from the tumor and non-tumor samples. Embodiments also include a method of treating cancer or preventing its relapse comprising administration of such a personalized cancer vaccine. The invention is of very special interest in the field of personalized immunotherapy.Type: GrantFiled: June 21, 2018Date of Patent: April 30, 2024Assignee: TransgeneInventors: Kaïdre Bendjama, Nathalie Silvestre, Jean-Baptiste Marchand, Benoît Grellier
-
Publication number: 20240024437Abstract: The present invention relates to a combination product, composition(s) and kit of parts comprising at least (i) a therapeutic vaccine and (ii) one or more immune checkpoint modulator(s). The present invention also concerns a method for treating a proliferative or an infectious disease as well as a method for eliciting or stimulating and/or re-orienting an immune response, wherein said methods comprise administering to a subject in need thereof said combination product or said composition(s).Type: ApplicationFiled: December 28, 2022Publication date: January 25, 2024Applicant: Transgene SAInventors: Philippe SLOS, Julie Hortelano, Karola Rittner, Xavier Preville
-
Patent number: 11779619Abstract: The present invention provides an oncolytic virus comprising nucleotide sequence(s) encoding one or more immune checkpoint modulator(s). It also concerns a pharmaceutical composition comprising effective amount of said oncolytic virus and, eventually, a pharmaceutically acceptable vehicle and its use for treating proliferative diseases such as cancers.Type: GrantFiled: December 23, 2019Date of Patent: October 10, 2023Assignee: Transgene SAInventors: Nathalie Silvestre, Michel Geist, Karola Rittner, Jean-Baptiste Marchand, Christine Thioudellet
-
Publication number: 20230277639Abstract: The present invention generally relates to a personalized cancer vaccine comprising a recombinant poxvirus encoding one or more neopeptide(s) or a composition comprising such a recombinant poxvirus and a pharmaceutically acceptable vehicle as well as the use of said personalized cancer vaccine for treating a cancerous subject in need thereof. A specific embodiment is directed to a method of providing such a vaccine or composition comprising an identification step comprising a) extracting the DNA from a tumor sample and a non-tumor sample, b) selecting target regions, c) sequencing said target regions from said extracted DNAs and d) identifying one or more tumor-specific mutation(s) by comparing the DNA sequences obtained from said tumor and non-tumor samples. Embodiments also include a method of treating cancer or preventing its relapse comprising administration of such a personalized cancer vaccine. The invention is of very special interest in the field of personalized immunotherapy.Type: ApplicationFiled: April 13, 2023Publication date: September 7, 2023Applicant: TransgeneInventors: Kaïdre Bendjama, Nathalie Silvestre, Jean-Baptiste Marchand, Benoît Grellier
-
Publication number: 20230256057Abstract: The present invention is in the field of immunotherapy. The invention provides non-propagative viral vectors comprising a nucleic acid molecule encoding at least a polypeptide having an IL-7 activity, wherein said non-propagative viral vector is for use in the treatment of immune depression induced by sepsis, burn, trauma, major surgery, senescence and/or coronavirus.Type: ApplicationFiled: July 13, 2021Publication date: August 17, 2023Applicant: TransgeneInventors: Geneviève INCHAUSPE, Perrine MARTIN, Stéphane LEUNG-THEUNG-LONG, Karine LELU-SANTOLARIA, Alexei EVLACHEV, Charles Antoine COUPET, Aurélie RAY, Clarisse DUBOIS
-
Publication number: 20230081457Abstract: The present invention generally relates to a process for designing a recombinant poxvirus for a therapeutic vaccine, i.e. personalized cancer vaccine, said recombinant poxvirus comprising one or more expression cassettes, each for expression of a fusion of a plurality of peptides, i.e.Type: ApplicationFiled: December 22, 2020Publication date: March 16, 2023Applicant: TRANSGENEInventor: Benoît Grellier
-
Publication number: 20220056481Abstract: The present invention is in the field of oncolytic viruses. The invention provides new poxviruses which are engineered to be defective for the function encoded by the M2L locus (i.e., m2 function). Such poxviruses lack a functional m2 binding activity to at least one or both of CD80 and CD86 co-stimulatory antigens. Said oncolytic poxviruses are preferably vaccinia virus having a total or partial deletion of the M2L locus. The present invention also relates to cells and compositions comprising such poxviruses and their use for treating proliferative diseases such as cancers and for preventing diseases (vaccination, especially in veterinary field). More precisely, the invention provides an alternative to the existing oncolytic viruses which are largely used in virotherapy. The m2-defective poxviruses are particularly useful for the expression of immunomodulatory polypeptides such as anti-CTLA-4 antibodies with the purposes of stimulating or improve immune response.Type: ApplicationFiled: December 27, 2019Publication date: February 24, 2022Applicant: TRANSGENEInventors: Patricia KLEINPETER, Jean-Baptiste MARCHAND, Christelle REMY, Doris SCHMITT
-
Publication number: 20210000937Abstract: The present invention is in the field of viral immunotherapy. The invention provides new pseudocowpox (PCPV) viruses, in particular recombinant PCPV, composition thereof as well as their therapeutic use for preventing or treating diseases, and, notably, proliferative diseases like cancers and restenosis and infectious diseases such as chronic ones. The present invention also provides methods for generating and amplifying such a PCPV and a method for eliciting or stimulating and/or re-orienting an immune response using such a PCPV. More specifically, the invention provides an alternative to the existing poxvirus vectors such as MVA (Modified Virus Ankara) and may be largely used for the therapeutic vaccination.Type: ApplicationFiled: March 17, 2019Publication date: January 7, 2021Applicant: TRANSGENEInventors: Karola RITTNER, Christelle REMY, Christine THIOUDELLET
-
Patent number: 10857226Abstract: The present invention provides a composition comprising hepatitis B virus (HBV) component(s), and which may be either nucleic acid- or polypeptide-based as well as nucleic acid molecules and vectors encoding such HBV component(s). It also relates to infectious viral particles and host cells comprising such nucleic acid molecules or vectors. It also provides composition and kits of parts comprising such nucleic acid molecules, vectors, infectious viral particles or host cells and the therapeutic use thereof for preventing or treating HBV infections.Type: GrantFiled: September 17, 2018Date of Patent: December 8, 2020Assignee: Transgene S.A.Inventors: Perrine Martin, Geneviève Inchauspe, Nathalie Silvestre, Doris Schmitt, Alexei Evlachev
-
Publication number: 20200376052Abstract: The present invention provides a combination comprising at least an oncolytic virus and one or more immune checkpoint modulator(s) for use for the treatment of a proliferative disease such as cancer. It also relates to a kit comprising said oncolytic virus and said one or more immune checkpoint modulator(s) in separate containers. It also concerns a pharmaceutical composition comprising effective amount of said oncolytic virus and said one or more immune checkpoint modulator(s).Type: ApplicationFiled: August 5, 2020Publication date: December 3, 2020Applicants: Institut Gustave-Roussy, Transgene SAInventors: Laurence Zitvogel, Xavier Preville, Laetitia Fend
-
Patent number: 10765710Abstract: The present invention provides a combination comprising at least an oncolytic virus and one or more immune checkpoint modulator(s) for use for the treatment of a proliferative disease such as cancer. It also relates to a kit comprising an oncolytic virus and one or more immune checkpoint modulator(s) in separate containers. It also concerns a pharmaceutical composition comprising effective amount of an oncolytic virus and one or more immune checkpoint modulator(s).Type: GrantFiled: July 16, 2015Date of Patent: September 8, 2020Assignees: Institut Gustave-Roussy, Transgene SAInventors: Laurence Zitvogel, Xavier Preville, Laetitia Fend
-
Patent number: 10765731Abstract: The present invention relates generally to novel immunogenic combinations comprising or encoding at least two heterooligomeric mycobacterial antigens and preferably a fusion polypeptide comprising said two heterooligomeric mycobacterial antigens, where the mycobacterial antigens are selected from the group of Esx, PE and PPE antigens of a Mycobacterium species, particularly a Mycobacterium of the tuberculosis complex such as Mycobacterium tuberculosis (Mtb). The present invention also relates to vectors, host cells and compositions comprising or encoding said immunogenic combination as well as to methods for expressing and producing it. The present invention also relates to methods of using said immunogenic combination, fusion polypeptide, vector, host cell, composition particularly for inducing or stimulating an immune response with the goal of providing a protective response against a Mycobacterium infection or any disease caused by or associated with a Mycobacterium infection.Type: GrantFiled: January 9, 2015Date of Patent: September 8, 2020Assignee: TRANSGENE SAInventors: Jean-Baptiste Marchand, Nathalie Silvestre, François Penin
-
Publication number: 20200197457Abstract: The present invention provides an oncolytic virus comprising nucleotide sequence(s) encoding one or more immune checkpoint modulator(s). It also concerns a pharmaceutical composition comprising effective amount of said oncolytic virus and, eventually, a pharmaceutically acceptable vehicle and its use for treating proliferative diseases such as cancers.Type: ApplicationFiled: December 23, 2019Publication date: June 25, 2020Applicant: Transgene S.A.Inventors: Nathalie Silvestre, Michel Geist, Karola Rittner, Jean-Baptiste Marchand, Christine Thioudellet
-
Patent number: 10662414Abstract: The present invention relates to polymerase HBV mutant polypeptides comprising a mutated polymerase domain which is functionally disrupted for polymerase activity and fusion proteins comprising such polymerase mutant polypeptide. The present invention also relates to a nucleic acid molecule and an expression vector for expressing said polymerase mutant polypeptide as well as a composition which can be used for eliciting an immune response to HBV with the goal of providing a protective or therapeutic effect against HBV infection.Type: GrantFiled: January 25, 2019Date of Patent: May 26, 2020Assignee: Transgene S.A.Inventors: Perrine Martin, Nathalie Silvestre, Jean-Baptiste Marchand
-
Publication number: 20200138923Abstract: The present invention generally relates to a personalized cancer vaccine comprising a recombinant poxvirus encoding one or more neopeptide(s) or a composition comprising such a recombinant poxvirus and a pharmaceutically acceptable vehicle as well as the use of said personalized cancer vaccine for treating a cancerous subject in need thereof. A specific embodiment is directed to a method of providing such a vaccine or composition comprising an identification step comprising a) extracting the DNA from a tumor sample and a non-tumor sample, b) selecting target regions, preferably the entire coding regions of the genome (exome), c) sequencing said target regions (e.g. the exome) from said extracted DNAs and d) identifying one or more tumor-specific mutation(s) by comparing the DNA sequences obtained from said tumor and non-tumor samples. Embodiments also include a method of treating cancer or preventing its relapse comprising administration of such a personalized cancer vaccine.Type: ApplicationFiled: June 21, 2018Publication date: May 7, 2020Applicant: TransgeneInventors: Kaïdre Bendjama, Nathalie Silvestre, Jean-Baptiste Marchand, Benoît Grellier
-
Patent number: 10555981Abstract: The present invention provides an oncolytic virus comprising nucleotide sequence(s) encoding one or more immune checkpoint modulator(s). It also concerns a pharmaceutical composition comprising effective amount of said oncolytic virus and, eventually, a pharmaceutically acceptable vehicle and its use for treating proliferative diseases such as cancers.Type: GrantFiled: July 16, 2015Date of Patent: February 11, 2020Assignee: Transgene S.A.Inventors: Nathalie Silvestre, Michel Geist, Karola Rittner, Jean-Baptiste Marchand, Christine Thioudellet
-
Patent number: 10517943Abstract: The present invention relates to liquid formulations of poxvirus, in particular vaccinia virus, stable during storage. Such stable liquid formulations comprise a) a poxvirus, preferably a vaccinia virus, b) a pharmaceutically acceptable buffer, c) a monovalent salt, d) a pharmaceutically acceptable disaccharide or sugar alcohol, and e) a pharmaceutically acceptable chelating agent, wherein the pH of the formulation is comprised between 6.5 and 8.5.Type: GrantFiled: December 1, 2015Date of Patent: December 31, 2019Assignee: Transgene S.A.Inventor: Mélina Chasle
-
Publication number: 20190328869Abstract: The present invention provides an immunotherapeutic composition for use in combination with one or more MDSC (Myeloid-derived suppressor cells) modulator(s) and a kit of parts comprising such components as well as methods using such components in combination. The invention also provides the use of Phosphodiesterase-5 (PDE5) inhibitors for reversing immunosuppression in chronic infectious diseases. The invention is of very special interest in treating or preventing diseases, especially chronic infectious diseases such as hepatitis B.Type: ApplicationFiled: October 10, 2017Publication date: October 31, 2019Applicant: Transgene SAInventors: Karine Lelu-Santolaria, Roland Kratzer, Perrine Martin
-
Publication number: 20190330655Abstract: The present invention relates to an oncolytic virus encoding a cytidine deaminase (CDAse) polypeptide, a composition comprising it, as well as their use for prophylactic or therapeutic purposes, and more particularly for the treatment of cancer. The present invention also provides a method for treating a disease or a pathologic condition comprising the administration of such an oncolytic virus or composition thereof and a process for preparing such an oncolytic virus.Type: ApplicationFiled: December 21, 2017Publication date: October 31, 2019Applicant: TRANSGENE SAInventors: Philippe ERBS, Johann FOLOPPE
-
Patent number: 10357555Abstract: The present invention relates generally to immunogenic combinations comprising at least five antigens of a Mycobacterium species as well as fusion thereof and nucleic acid molecules encoding such combined antigens and fusion. The present invention also relates to nucleic acid molecules, vectors, host cells and compositions comprising or encoding said combinations of mycobacterial antigens and fusion polypeptides as well as to methods for recombinantly producing them. The present invention also relates to methods of using said combinations of mycobacterial antigens, fusion polypeptides, vectors, host cells, compositions particularly for inducing or stimulating an immune response against a Mycobacterium infection or any disease caused by or associated with a Mycobacterium infection.Type: GrantFiled: July 10, 2013Date of Patent: July 23, 2019Assignee: TRANSGENE SAInventors: Emmanuel Tupin, Romain Micol, Charles Antoine Coupet, Geneviève Inchaupse, Marie Gouanvic, Nathalie Silvestre, Jean-Baptiste Marchand, Cécile Beny